ScrutarSign up free

ABBV SEC Filings

SEC filings for ABBV. Annual and quarterly reports, 8-K events, Form 4 insider filings and 13D/G stake disclosures.

All10-K10-Q8-KProxyForm 413D/GLast 12 months
FormFiledAccession
10-QAIThe tone is upbeat and assertive, built on 11% revenue growth, strong Skyrizi and Rinvoq performance, a dividend increase, a credit rating upgrade and many pipeline wins.Nov 3, 2026EDGAR
8-KNov 2, 2026EDGAR
8-KOct 30, 2026EDGAR
8-KOct 16, 2026EDGAR
8-KOct 5, 2026EDGAR
8-KAIAbbVie Inc. announced the completion of its acquisition of Apogee Therapeutics, Inc. on September 3, 2026, disclosed via press release under Regulation FD.Sep 3, 2026EDGAR
4Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICERAug 18, 2026EDGAR
8-KAug 18, 2026EDGAR
8-KAug 5, 2026EDGAR
10-QAIManagement presents a strong, growth-oriented quarter.Aug 3, 2026EDGAR
8-KAIAbbVie Inc. filed an 8-K disclosing that on July 31, 2026 it issued a press release announcing its financial results for the second quarter ended June 30, 2026.Jul 31, 2026EDGAR
8-KAIAbbVie disclosed that Q2 2026 GAAP and adjusted non-GAAP earnings will include $291 million in pre-tax acquired IPR&D and milestones expense, reducing diluted EPS by $0.17.Jul 6, 2026EDGAR
8-KAIAbbVie disclosed a definitive agreement to acquire Apogee Therapeutics, announced via a joint press release and investor presentation on June 22, 2026.Jun 22, 2026EDGAR
4FALK THOMAS JMay 12, 2026EDGAR
4WADDELL FREDERICK HMay 12, 2026EDGAR
4Roberts Rebecca BMay 12, 2026EDGAR
4RAPP EDWARD JMay 12, 2026EDGAR
4Quaggin Susan EMay 12, 2026EDGAR
4MEYER MELODY BMay 12, 2026EDGAR
4Hart Brett JMay 12, 2026EDGAR
4FREYMAN THOMAS CMay 12, 2026EDGAR
4Davis Jennifer L.May 12, 2026EDGAR
4BURNSIDE WILLIAM H.L.May 12, 2026EDGAR
4AUSTIN ROXANNE SMay 12, 2026EDGAR
8-KMay 12, 2026EDGAR
10-QAIAbbVie's tone is positive and assertive: 12% revenue growth, strong Skyrizi and Rinvoq performance, higher operating cash flow and a Moody's upgrade.May 8, 2026EDGAR
SC 13GVanguard Capital ManagementApr 29, 2026EDGAR
8-KAIAbbVie Inc. announced its financial results for the first quarter ended March 31, 2026 via a press release issued on April 29, 2026.Apr 29, 2026EDGAR
8-KApr 3, 2026EDGAR
SC 13G/AamendedThe Vanguard GroupMar 26, 2026EDGAR
DEF 14AMar 23, 2026EDGAR
4/APurdue David RyanSVP, ControllerMar 11, 2026EDGAR
4Purdue David RyanSVP, ControllerMar 6, 2026EDGAR
4Crum Demetris DEVP, CHIEF HR OFFICERMar 6, 2026EDGAR
8-KMar 4, 2026EDGAR
4Thakkar RoopalEVP, R&D and CSOMar 3, 2026EDGAR
4Michael Robert A.CHAIRMAN OF THE BOARD AND CEOMar 3, 2026EDGAR
4Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICERMar 3, 2026EDGAR
4Siatis Perry CEVP, GC AND SECRETARYMar 3, 2026EDGAR
4Reents Scott TEVP, CHIEF FINANCIAL OFFICERMar 3, 2026EDGAR
4SALEKI-GERHARDT AZITAEVP, CHIEF OPERATIONS OFFICERMar 3, 2026EDGAR
4Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICERMar 3, 2026EDGAR
4Siatis Perry CEVP, GC AND SECRETARYFeb 27, 2026EDGAR
8-KFeb 26, 2026EDGAR
4Thakkar RoopalEVP, R&D and CSOFeb 20, 2026EDGAR
4Purdue David RyanSVP, ControllerFeb 20, 2026EDGAR
4Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICERFeb 20, 2026EDGAR
4Siatis Perry CEVP, GC AND SECRETARYFeb 20, 2026EDGAR
4SALEKI-GERHARDT AZITAEVP, CHIEF OPERATIONS OFFICERFeb 20, 2026EDGAR
4Crum Demetris DEVP, CHIEF HR OFFICERFeb 20, 2026EDGAR
4Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICERFeb 20, 2026EDGAR
4Reents Scott TEVP, CHIEF FINANCIAL OFFICERFeb 20, 2026EDGAR
4Michael Robert A.CHIEF EXECUTIVE OFFICERFeb 20, 2026EDGAR
10-KAIAbbVie's MD&A is moderately positive: 9% revenue growth, Skyrizi and Rinvoq momentum, a favorable U.S. government agreement, a Moody's upgrade and a strong pipeline.Feb 20, 2026EDGAR
8-KAIAbbVie Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025 via a press release issued on February 4, 2026.Feb 4, 2026EDGAR
8-KJan 7, 2026EDGAR

SEC filings for companies related to ABBV

LLYELI LILLY & CoBMYBRISTOL MYERS SQUIBB COPFEPFIZER INCMRKMerck & Co., Inc.AMGNAMGEN INCJNJJOHNSON & JOHNSONGILDGILEAD SCIENCES, INC.REGNREGENERON PHARMACEUTICALS, INC.

Never miss a ABBV filing.

Get an email when ABBV files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.

Free foreverNo account requiredOne-click unsubscribe

Protected by reCAPTCHA. Privacy & Terms

Source: SEC EDGAR.